Physician profile
Dindial Singh
NPI 1548288616
$4,074.09
in general payments reported to CMS, 2019-2025
13 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $983 · 2020: $398 · 2021: $673 · 2022: $1,245 · 2023: $547 · 2024: $64.02 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $898.62 | 2019-2024 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $842.20 | 2019-2023 | Austedo |
| Alkermes, INC. | $597.39 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $479.87 | 2019-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $384.93 | 2019-2023 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $249.99 | 2019 | |
| Indivior INC. | $144.77 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $130.88 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.84 | 2022 | |
| Sunovion Pharmaceuticals INC. | $78.56 | 2019-2020 | |
| Lundbeck LLC | $61.07 | 2019-2023 | Abilify Maintena |
| Vanda Pharmaceuticals INC. | $56.31 | 2020-2021 | |
| Bioxcel Therapeutics, INC. | $23.66 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dindial Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.